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Bacterium Chlamydia pneumoniae
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Institute of Health and Biomedical Innovation, School of Biomedical Sciences, Faculty of Health, Queensland University of Technology, Kelvin Grove, Queensland,
Australiaa; Faculty of Science, Health, Education & Engineering, University of the Sunshine Coast, Maroochydore, Queensland, Australiab
The chlamydiae are obligate intracellular parasites that have evolved specific interactions with their various hosts and host cell
types to ensure their successful survival and consequential pathogenesis. The species Chlamydia pneumoniae is ubiquitous, with
serological studies showing that most humans are infected at some stage in their lifetime.While most human infections are
asymptomatic, C. pneumoniae can cause more-severe respiratory disease and pneumonia and has been linked to chronic dis-
eases such as asthma, atherosclerosis, and even Alzheimer’s disease. The widely dispersed animal-adapted C. pneumoniae strains
cause an equally wide range of diseases in their hosts. It is emerging that the ability of C. pneumoniae to survive inside its target
cells, including evasion of the host’s immune attack mechanisms, is linked to the acquisition of key metabolites. Tryptophan and
arginine are key checkpoint compounds in this host-parasite battle. Interestingly, the animal strains of C. pneumoniae have a
slightly larger genome, enabling them to cope better with metabolite restrictions. It therefore appears that as the evolutionarily
more ancient animal strains have evolved to infect humans, they have selectively becomemore “susceptible” to the levels of key
metabolites, such as tryptophan. While this might initially appear to be a weakness, it allows these human C. pneumoniae strains
to exquisitely sense host immune attack and respond by rapidly reverting to a persistent phase. During persistence, they reduce
their metabolic levels, halting progression of their developmental cycle, waiting until the hostile external conditions have passed
before they reemerge.
The genusChlamydia contains a phylogenetically unique groupof obligate intracellular parasites that successfully infect hu-
mans and a wide range of animals. They are characterized by their
unique developmental cycle, which consists of two morphologi-
cally distinct forms (reviewed in reference 1). The extracellular,
infectious form (elementary body [EB]) is responsible for trans-
mitting infections between cells and betweenhosts and is generally
considered to be metabolically inert (although this has been chal-
lenged recently [2]), whereas the intracellular, noninfectious form
(reticulate body [RB]) is metabolically active and is responsible
for growth and multiplication within the target host cell (Fig. 1).
Once an EB attaches to and enters a host cell, it immediately hi-
jacks several host cell pathways (3, 4), preventing phagolysosomal
fusion, encasing itself in a unique double-membrane inclusion
and rapidly converting to the metabolically active, RB form. The
RBs multiply by binary fission around 500-fold during a 24-to-
48-h period before converting back to EBs, which subsequently
exit the cell to start another round of multiplication. This unique
“acute” developmental cycle has both strengths and weaknesses.
Once inside a suitable host cell, provided the chlamydiae can sub-
vert several key host cell pathways, they generally have access to a
rich pool of nutrients required for growth. While the chlamydiae
have retained a diverse set of metabolic pathways, they have also
lostmany pathways,making themdependent on their host cell for
a significant number of key nutrients and intermediates. Of
course, eukaryotic cells have evolved a range of strategies to com-
bat pathogens such as Chlamydia (reviewed in reference 5). One
main line of defense is that eukaryotic cells sense foreign invaders
(via pattern recognition receptor [PRR] signaling), resulting in
production of the key cytokine gamma interferon (IFN-) (at
least in humans), which in turn depletes the host cell tryptophan
(TRP) pool and effectively starves the foreign bacteria of this key
nutrient.
In addition to the acute developmental cycle, chlamydiae have
also developed a so-called “persistent phase” (6, 7). While this
persistent phase has been best studied in vitro, it can also be ob-
served in vivo (7–12). Chlamydial persistence has been described
as “a viable but non-culturable growth stage resulting in a long
term relationship with the infected host cell” (13). During persis-
tence, chlamydialmetabolism is slowed and RB division, as well as
differentiation into EBs, is suspended (6, 14, 15), resulting in the
production of so-called aberrant bodies. Overall, this means that
while the RBs are metabolically viable, they do not complete the
developmental cycle and hence no infectious progeny are pro-
duced. This state is reversible. Several different stimuli have been
shown to induce persistence, including (i) gamma interferon
treatment, (ii) penicillin treatment, (iii) amino acid (e.g., trypto-
phan), glucose, and iron deprivation, (iv) chlamydiophage infec-
tion, and several others (14, 16–26). Persistence therefore appears
to be a mechanism that allows the organisms to ride out hostile
conditions while maintaining a long-term (chronic) infection
within a host cell.
Of the nine species in the genus Chlamydia, C. pneumoniae is
arguably the most successful pathogen, infecting humans and an
amazingly wide range of animals. In humans, serological studies
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show that almost all of the world’s population is, or had been,
infected with C. pneumoniae (27). Respiratory infections are the
most common, with seroepidemiological surveys indicating that
infection is both endemic and epidemic. Asymptomatic infections
are common, usually manifesting as mild upper tract infections that
are self-limiting, although they may progress to more-severe upper
respiratory tract infections (pharyngitis, sinusitis, and otitis) and
lower respiratory tract infections (acute bronchitis, exacerbations of
chronic bronchitis and asthma, and community-acquired pneumo-
nia) (28–37). The species was initially “discovered” in Finland in
1985, where it caused epidemics of pneumonia in military barracks
(38), and, after its initial worldwide characterization (39–42), was
thought to have declined somewhat in prevalence. However, recent
reports (both serological studies and studies of outbreaks in con-
fined populations [43, 44]) show that it is still a widespread and
successful respiratory pathogen. In addition to respiratory in-
fections, C. pneumoniae has been linked with several other
chronic conditions, most notably cardiovascular inflammatory
diseases such as atherosclerosis, abdominal aortic aneurisms, and
valvular lesions (45–48). While there is a body of published evi-
dence linking C. pneumoniae and cardiovascular disease, a causal
link remains to be definitively proven and is considered contro-
versial by some. In addition to the link with cardiovascular dis-
eases, it has also been linkedwith asthma (49), Alzheimer’s disease
(50, 51), arthritis (52), lung cancer (53–55), chronic obstructive
pulmonary disease (56, 57), and diabetes (58, 59). While there
continue to be individual reports of severe respiratory disease as-
sociated with C. pneumoniae (60), it appears that the norm is now
an association of C. pneumoniae with a range of chronic diseases.
In addition to its widespread prevalence in the human popu-
lation, C. pneumoniae also causes infection and disease in a wide
range of animals. C. pneumoniae infections have been reported in
both cold-blooded hosts (frogs, snakes, iguanas, and crocodiles
[61–63]) and warm-blooded hosts (horses and marsupials [63–
67]). In these animal hosts, it infects a wide range of tissues (lung,
liver, heart, eyes, and the female genital tract of koalas) and causes
awide range of disease syndromes (respiratory, vascular, conjunc-
tival, genitourinary, and systemic).
Hypothesis: Chlamydia pneumoniae—a highly successful
parasite with “50 shades of gray.” The hypothesis which we dis-
cuss in this review is that the highly successful obligate intracellu-
lar pathogen, C. pneumoniae, has actually evolved an increasing
susceptibility to tryptophan, the key amino acid. Rather than
making this tryptophan auxotroph more vulnerable to host “at-
tack,” it has enabled the evolution of the more ancient, animal
infection strains (which are less sensitive to tryptophan availabil-
ity and cause more acute infections) into the currently successful
human strains. The human strains not only are more sensitive to
tryptophan availability but primarily cause chronic infections that
are exquisitely in balance with their host.
TRYPTOPHAN IS AN ESSENTIAL AMINO ACID AND A
CENTRAL REGULATOR FOR CELL BIOLOGY
Humans and animals lack the ability to synthesize the essential
amino acid tryptophan. Consequently, tryptophan depletion
acts as a major cellular signal. In humans, tryptophan depletion
is associated with depression and other neurological conse-
quences (68, 69). At a cellular level, reduction of intracellular
tryptophan pools initiates molecular stress response pathways
(via GCN2 kinase and mammalian target of rapamycin
[mTOR] signaling molecules), resulting in blockage of ribo-
somal translation and cell cycle arrest. Localized tryptophan
deprivation can also initiate these stress response pathways in
local T cells, leading to arrest and promotion of regulatory T
cell differentiation. Furthermore, bioactive tryptophan metab-
olites (produced from the kynurenine [KYN] pathway) have
been found to have direct immunosuppressive capabilities, fa-
cilitating promotion of regulatory T cell differentiation (re-
viewed in references 70 and 71). In spite of these consequences,
tryptophan is also actively depleted by animal cells in a patho-
gen defense strategy. Most bacteria are able to synthesize tryp-
tophan and can partially overcome the host’s efforts to starve it
of tryptophan. However, some microbes, such as Chlamydia,
are full or partial tryptophan auxotrophs. In fact, Chlamydia have
unique host- and tissue niche-specific requirements, intrinsically
based on differential abilities to synthesize tryptophan (or not)
from metabolites or bioavailable intermediates.
FIG 1 The central role of tryptophan in chlamydial biology. Chlamydial elementary bodies attach to and enter a host epithelial cell, an inclusion is formed, and
the elementary body (EB) converts to its replicative form, the reticulate body (RB). RBs undergo replication; however, during infection, PRRs are activated,
resulting in secretion of proinflammatory cytokines from the host, which in turn recruits immune cells. Development of an immune response results in host cells
being exposed to gamma interferon. IDO is activated, and tryptophan pools are depleted. (A) The species C. caviae, C. pecorum, and C. felis obtain kynurenine
(the product of IDO activity) from the host cell and use it to recycle tryptophan via tryptophan biosynthesis genes (kynU and trpD, -F, -C, -A, and -B), meaning
that these species are able to actively replicate during IDO activity and host tryptophan depletion. This tryptophan biosynthesis process is regulated by a
tryptophan repressor and thus is initiated only when inclusion tryptophan levels become depleted. (B) The urogenital strains of C. trachomatis are believed to
respond to IDO-tryptophan depletion by using indole (thought to be supplied by the vaginal microflora) as a precursor for tryptophan synthesis. Tryptophan
synthesis is achieved through the tryptophan biosynthesis genes trpA and -B. As with the above-mentioned species,C. trachomatis tryptophan biosynthesis is also
regulated via a tryptophan repressor that allows biosynthesis to occur only once inclusion tryptophan levels become depleted. Interestingly, the ocular C.
trachomatis strains do not possess the tryptophan biosynthesis genes and are associated with more-chronic disease outcomes. (C) The key role of tryptophan in
C. pneumoniae chronic infection. In stark contrast to the above-mentioned species, C. pneumoniae does not contain any tryptophan biosynthesis genes. As a
result, tryptophandepletion results in conversion of an active replicating inclusion to a persistent inclusion (a viable but nonreplicating, static phase). In this state,
C. pneumoniae becomes refractory to immune insult, allowing the organism to hide in the host cell until the immune response subsides. As the immune response
abates, IFN- becomes depleted, IDO is no longer induced, local tryptophan pools become recharged, and tryptophan levels eventually return to normal. At this
point, C. pneumoniae reverts to an actively replicating inclusion, resulting in the release of infectious progeny ready to reinitiate the chronic infection cycle. (D)
Recent studies have found that human and animal (ancestral) strains behave very differently in the face of IFN- insult and tryptophan depletion. This finding
suggests that the human strains have evolved to become more sensitive to IFN-, allowing them to enter a persistent phase at the first signs of an immune
response. As a result, they have been able to develop a chronic infection cycle that has enabled them to become, arguably, one of the most successful human
pathogens. EB, elementary body; RB, reticulate body; IFN-g, gamma interferon; IL, interleukin; PRR, pattern recognition receptors; IDO, indoleamine 2,3-
dioxygenase; TRP, tryptophan; KYN, kynurenine; KYN-M, kynurenine metabolites.
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PATHOGEN DEFENCE VIA IDO (INDOLEAMINE 2,3-
DIOXYGENASE)-MEDIATED TRYPTOPHAN DEPLETION
Chlamydial infection of mucosal epithelial cells results in activa-
tion of innate, pathogen-sensing PRRs. Activation of these recep-
tors initiates an immunological cascade, resulting in expression
and secretion of cytokines and chemokines (reviewed in reference
5) and recruitment of leukocytes (NK cells, neutrophils, macro-
phages, and dendritic cells) to the infected tissue (72). An adaptive
immune response is then initiated via antigen-processing cells
presenting chlamydial antigens to T cells in local lymph nodes.
Animal studies (73–76) and, to a certain degree, human studies
(73–78) have found that IFN--producing T cells are essential for
resolution of chlamydial infections (72, 79, 80).
The antichlamydial effect of IFN- is attributed predomi-
nantly to direct inhibition of intracellular growth. Exposure of the
host cells to IFN- results in induction of a myriad of responses
(81). However, it is the induction of IDO (indoleamine 2,3-dioxy-
genase) (82) and inducible nitric oxide synthase (iNOS) (83) and
downregulation of transferrin receptors (84) that is central to in-
tracellular inhibition of chlamydial growth. IDO is a heme-con-
taining, cytosolic, IFN--inducible enzyme that catalyzes the
breakdown of the essential amino acid tryptophan to kynurenine
via the cleavage of the pyrrole ring. Kynurenine is then released
from the cell or furthermetabolized to the downstreamcatabolites
3-hydroxykynurenine, 3-hydroxyanthranilic acid, quinolinic
acid, and, finally, NAD (i.e., the kynurenine pathway).
More than 2 decades ago, tryptophan depletion, via IFN- in-
duction of IDO, was described as a possible mechanism for inhib-
iting intracellular growth of the parasite Toxoplasma gondii (85).
The simplistic paradigmof IDObeing a host innate defensemech-
anism, using essential amino acid deprivation as a means to con-
trol tryptophan auxotrophic intracellular pathogen replication,
has been superseded recently by a more complex model. Specifi-
cally, IDO tryptophan catabolism has been found to have far-
ranging effects making it a pivotal component in immune and
cellular regulation via the aforementioned signaling mechanisms.
Consequently, IDO-tryptophan depletion has been found to have
an important role in parasitic (86), viral (87), and bacterial (88,
89) infections. Although most reports document pathogen sensi-
tivity to tryptophan depletion, recent studies are finding a role for
IDO activity in chronic or persistent disease. In particular, IDO-
tryptophan-directed immunosuppression is thought to play a role
in infections by Leishmania major (90), human immunodefi-
ciency virus (reviewed in reference 91), hepatitis C virus (92, 93),
human papillomavirus (94), Listeria monocytogenes (95), Myco-
bacterium tuberculosis (96), Candida albicans (97), and Aspergillus
fumigatus (98). Importantly, a recent study investigating the role
IDO plays in infections by two protozoal species, T. gondii and L.
major, found that IDO facilitates T. gondii clearance and sup-
presses L. major clearance, highlighting the opposing and patho-
gen-specific roles that IDO can have in infectious disease (90).
IFN-- and IDO-directed tryptophan depletion has had a sig-
nificant effect on chlamydial evolution. In vitro model studies of
epithelial cells, using tryptophan rescue of IFN--treated cultures,
indicate that tryptophan depletion is the major antipathogen ac-
tivity of IFN- againstChlamydia (88, 89). The human ocular and
urogenital pathogen Chlamydia trachomatis contains tryptophan
synthesis (trpBA) genes allowing synthesis of tryptophan from
indole (99). However, this adaptation was found to be functional
only in the urogenital strains. It was proposed that the urogenital
strains gain access to indole via vaginal microflora, thus identify-
ing a tissue tropismmediator (i.e., ocular versus urogenital) (100).
Interestingly, the ocular strains (serovars A to C) responsible for
the chronic disease trachoma appear to bemuchmore sensitive to
the effects of IFN- than the urogenital strains (101). Another
chlamydial species, Chlamydia caviae (guinea pig), has also
evolved an elegant adaptation to tryptophan depletion, utilizing a
more complete set of tryptophan synthesis genes (102, 103). These
genes allow this species to recycle kynurenine back into trypto-
phan, ensuring continued propagation in the presence of IFN-
induced IDO (104). Although not yet experimentally tested, these
recycling genes are also conserved on the genomes of Chlamydia
pecorum (sheep, cattle, koala), and Chlamydia felis (cats). Even
though these tryptophan anabolism capabilities are present across
these diverse animal-infecting species of Chlamydia, the situation
is different for the murine strain, where IFN- inhibition ofChla-
mydia in murine cells is driven by p47 GTPases and not IDO
(105). The murine pathogen (Chlamydia muridarum) produces a
species-specific cytotoxin that is thought to degrade the key p47
GTPase, enabling continued propagation in the presence of IFN-
(105).
In stark contrast, C. pneumoniae, arguably the most successful
human pathogen in theChlamydia genus, does not have any tryp-
tophan biosynthesis genes. As we discuss below, this apparent vul-
nerability to tryptophan may in fact be a checkpoint system for
sensing danger in the form of the presence of someC. pneumoniae
strains (particularly the human strains). Nevertheless, C. pneu-
moniae requires a certain amount of tryptophan for survival and
one possibility is that it can perhaps utilize the respiratory micro-
flora to obtain its tryptophan. Themicroflora of the human respi-
ratory tract is less well characterized than for other body sites, but
it is known to be quite complex and contains bacteria that produce
tryptophan, which could be transported from the microbiome
environment into the Chlamydia-infected cell/inclusion by vari-
ous C. pneumoniae transporters.
HAVE THE HUMAN STRAINS OF C. PNEUMONIAE ACTUALLY
EVOLVED TOWARD AN INCREASED SENSITIVITY TO
TRYPTOPHAN AVAILABILITY, ENABLING THEM TO SWITCH
FROM ACTIVE GROWTH TO THE LATENT PHASE AND
THEREBY BECOME MORE SUCCESSFUL CHRONIC
“PATHOGENS”?
The animal strains of C. pneumoniae are evolutionarily older
and have a slightly larger genome. Several strains of C. pneu-
moniae have now had their full genomes sequenced (106), includ-
ing four human strains (107–109) and two animal strains (110,
111). While the genomes are remarkably similar (99% identity
in gene content and arrangement), there are some subtle but pre-
sumably significant differences between the human and animal
strains but also between the various human strains.
One striking feature of allC. pneumoniae strains is that they are
complete tryptophan auxotrophs. Perhaps the most interesting
outcome of comparisons of the genomes of the human and animal
strains of C. pneumoniae, though, is the evidence that the animal
strains are evolutionarilymore ancient and that the human strains
probably evolved from the animal strains, perhaps over a relatively
recent and short time period, by reducing their gene content and
presumably adapting specifically to the human host (110). The
animalC. pneumoniae genome is 1,241,024 bp in size, which is just
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10 kb larger than the human C. pneumoniae genome, with just
6,213 single nucleotide polymorphisms (SNPs) separating the
strains (110). A potentially important difference, though, is that
the animal strains contain a plasmid whereas all human strains do
not. While the genes in the C. pneumoniae plasmid have not yet
been characterized, they have significant homology to the C. tra-
chomatis plasmid genes. TheC. trachomatis plasmid genes are cur-
rently the focus of considerable research, and it appears that some
of these plasmid genes have roles in regulating chromosomal
genes. As chlamydial transformation techniques are refined, it
should become possible to test plasmidless animal strains for their
response to IFN- and tryptophan. The other key difference is that
there are several examples of genes that are full length in the ani-
mal strain but have truncations or significant disrupting fragmen-
tations in the human strains. These facts have led investigators to
conclude that the animal strains are ancestral and that the human
strains evolved from them, adapting specifically to the human
host as they have evolved (110).
Recent cell biology studies support the suggestion that the
human strains of C. pneumoniae are more sensitive to exoge-
nous tryptophan levels than the animal strains. In 2008,Mitchell
et al. analyzed the in vitro growth of the animal strain of C. pneu-
moniae and compared it to that of the AR39 human strain (112).
They observed significant growth differences, with the animal
strain growing more aggressively, with a shorter doubling time
(3.4 to 4.9 h versus 5.9 to 8.7 h), producing larger inclusions and a
higher yield of infectious progeny than the human strain, which
generally produced small inclusions with a lower infectious yield
(112).
C. pneumoniae human isolates have been reported to be ex-
tremely sensitive to tryptophan depletion via IFN--induced IDO
(113–115). In vitro studies with epithelial and endothelial cell
lines, utilizing IDO inhibition and tryptophan supplementation,
have found human C. pneumoniae strains to be highly sensitive to
IDO-driven tryptophan depletion (113, 115, 116). A recent study
investigated the different effects that amino acid supplementation
had onC. trachomatis andC. pneumoniae. Somewhat surprisingly,
the addition of excess tryptophan was found to marginally inhibit
C. trachomatis growth whereas, in contrast, it significantly en-
hanced C. pneumoniae growth (117). C. pneumoniae tissue tro-
pismmay also be influenced by the ability of the organism to gain
access to host tryptophan, as the vascular strains only carry a single
copy of the tryptophan-tyrosine permease (versus two copies in
the respiratory strain), potentially resulting in reduced amino acid
uptake ability in the vascular isolates (118).
Like other chlamydial species, C. pneumoniae can enter a state
of persistence (i.e., a noninfectious but viable state) during IFN-
insult (reviewed in references 13, 119, and 120). This persistent
state can be reversed and active replication reinstated through the
addition of tryptophan or via the inhibition of IDO (113, 115,
116). Unsurprisingly, due to the lack of tryptophan biosynthesis
genes, only very low levels (15 to 25U/ml) of IFN- are required to
induce altered inclusion morphology (associated with persistent
infection) in in vitro epithelial cell models (20, 113). However, if
the organisms are exposed to IFN- during infection, a total bac-
tericidal effect requires very high levels (800U/ml) of IFN- (113).
A recent study investigating the cell biology differences be-
tween the ancestral animal strains and the more recently evolved
human strains of C. pneumoniae has confirmed the sensitivity of
the human strains to IFN- under controlled in vitro conditions
(A. Chacko, C. J. Barker, K. Beagley, P Timms, andW.M.Huston,
submitted for publication). The human strains of C. pneumoniae
are exquisitely sensitive to the reduction in the tryptophan level
via the effects of IFN-. The number and size of chlamydial inclu-
sions are decreased (some appear persistent), and their infectious
yield is markedly reduced (by greater than 99.99%). By compari-
son, the ancestral animal strain, under the same conditions, is
much less affected by IFN- treatment (with approximately 100-
fold-greater infectious yield). Interestingly, they also showed that
subtle differences in IFN- sensitivity exist between the various
human strains (comparing a respiratory isolate with a cardiovas-
cular isolate). By using direct depletion of tryptophan from the
medium, those researchers demonstrated that the IFN- effect
was clearly associated with tryptophan depletion (Chacko et al.,
submitted). Furthermore, adding additional exogenous trypto-
phan back to the human strains actually increased their infectious
yield above that produced by the non-IFN--treated controls
(Chacko et al., submitted). Themechanism bywhich the ancestral
animal strains obtain sufficient tryptophan is not yet clear; how-
ever, increased host cell autophagy and effective transport from
the host cell pool into the chlamydial inclusion is one possibility.
This “strategy” enables the animal strains to grow basically as an
acute infection, producing highly infectious outcomes, whereas
the human strains prefer to sense adverse conditions (such as host
immune attack via IFN-) by being more sensitive to lowering
levels of tryptophan, diverting them from completing their infec-
tious cycle and returning them to their persistent stage, where they
wait out the unfavorable conditions.
These recent findings suggest that the ancestral strains are less
“dependent” on exogenous tryptophan levels and prefer to grow
as acute infections, ensuring their survival by completing their
developmental cycle with the production of large numbers of in-
fectious progeny to infect other cells or new hosts. In contrast, the
evolution of the human strains has resulted in their being more
“sensitive” to decreasing exogenous tryptophan levels, allowing
them to sense adverse conditions (such as host immune attack via
IFN-). These strains use the lowering levels of tryptophan to
divert their infectious life cycle to a persistent phase until the ad-
verse conditions subside. Increases in tryptophan levels then trig-
ger reactivation of the developmental cycle, making the human
strains more likely to cause chronic infections.
SUBTLE VARIATIONS IN THE TRYPTOPHAN CONTENT OF
KEY CHLAMYDIAL PROTEINS COULD BE A FUNDAMENTAL
DETERMINANT OF SUSCEPTIBILITY TO LIMITED
TRYPTOPHAN AVAILABILITY
Several reviews have emerged recently (121, 122) suggesting that
the chlamydial genus as a whole may have evolved a mechanism
that mutes or downregulates selected gene products via the tryp-
tophan levels in these key proteins. Those proteins that are re-
quired during the acute or active growth phase (i.e., normal de-
velopment of Chlamydia) have higher tryptophan content, since
tryptophan availability is less of an issue in this stage of growth.
However, when the host responds to chlamydial infection by pro-
ducing IFN- and tryptophan is depleted, these proteins become a
burden to the Chlamydia and this triggers their switch from the
acute to the persistent phase. In the persistent phase, a different
subset of proteins are required and these have a lower tryptophan
content (at least, the high-tryptophan-containing proteins are not
highly expressed in this phase), making these proteins less of a
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metabolic burden to produce during a time when tryptophan lev-
els are limited. While this provocative hypothesis seems to fit the
C. trachomatis data best, it may also be partly supported by the
limited C. pneumoniae data that are available. Lo et al. (121) re-
ported that MurA is a low-tryptophan-containing enzyme, mak-
ing it more suited to expression during persistence. Indeed, when
Timms et al. (123) evaluated murA transcription in the IFN-
model ofC. pneumoniae, they found that it was upregulated 2-fold
under these conditions. While this hypothesis is interesting to
consider, at this stage it is built entirely on bioinformatic analysis
of chlamydial genomes and is not yet supported by any focused
biological data. In addition, while it might be a general strategy
used by chlamydiae, a comparison of the human and animal C.
pneumoniae genomes does not support an extension of this tryp-
tophan skew in the acute animal strains.
ARGININE AND THE IDO-TRYPTOPHAN NEXUS
C. pneumoniae also appears to have unique arginine-related adap-
tations. This species has a functional arginine-responsive tran-
scriptional repressor (124) and an arginine decarboxylase and ar-
ginine-agmatine antiporter (125). In addition, excess exogenous
arginine causes significant growth inhibition in vitro (117). The
ability to take up and degrade arginine is most likely a means of
protection against the host cell pathogen oxidative attack com-
pound nitric oxide (NO) (125). Immune signaling activates tran-
scription of iNOS, which catabolizes arginine to citrulline, pro-
ducing NO. Importantly, NO directly inhibits IDO activity via
binding to the active-site heme (126). An in vitro study found that
exogenous NO is able to inhibit IDO tryptophan catabolism, re-
sulting in nearly normal C. trachomatis L2 growth in epithelial
cells (C. trachomatis L2 does not have a functional arginine decar-
boxylase [127, 128]). Even with these adaptations to prevent NO
attack, macrophages from iNOS/mice are more susceptible to
C. pneumoniae infections in vitro (129, 130). Nonetheless, it is
clear that C. pneumoniae can reduce host arginine levels, thereby
reducing NO production and, paradoxically, allowing continued
IDO activity, perhaps as a direct trigger for chronic or persistent
growth. These arginine-based adaptations have not been exten-
sively investigated but seem likely to also function in the shades of
gray between acute and chronic disease states and tissue adapta-
tions that exist within the ubiquitous C. pneumoniae strains.
CONCLUSION
Tryptophan availability and the ability to overcome active trypto-
phan depletion fundamentally define host and tissue tropism and,
therefore, pathogenicity for Chlamydia. Here we discuss the hy-
pothesis that sensing tryptophan bioavailabilty to trigger chronic
growth or persistence has been selected for as a chronic disease
advantage in human C. pneumoniae infections. We already know
that ocularC. trachomatis strains aremore sensitive to IFN- than
the closely related genital strains and that they aremore chronic in
their growth and disease states. At the other end of the spectrum,
the ancestral animal C. pneumoniae strains appear to have been
selected for a more aggressive, acute disease state. Recent data
demonstrate that animalC. pneumoniae strains are less sensitive to
tryptophan depletion than the human C. pneumoniae strains, are
more aggressive in their growth, and present with more acute
disease. The versatile and highly prevalent human C. pneumoniae
strains are clearly advantaged by this tryptophan-responsive
chronic disease trigger, which may in fact be further adapted with
tissue tropism and disease states within these strains. While this
model is appealing and is quite well supported by the currently
published literature, further studies are needed to confirm it and
to better understand the molecular mechanisms involved. As the
technique of chlamydial transformation becomes more widely
used, evaluating plasmidless or gene knockout strains would be
one way of addressing these issues.
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